Abstract The objective of this study is to describe the neuropathologic findings in three LRRK2 G2019S carriers with Parkinson's disease (PD). We cross-referenced a list of 956 PD individuals that had been previously genotyped in clinical studies at Columbia University, with 282 subjects with a parkinsonian syndrome who came to autopsy in our brain bank since 1991. We found three autopsies of G2019S mutation carriers. Pathological analyses of the samples were blind to the genetic findings. We retrospectively reviewed the clinical records of the three patients. All three had a clinical and pathological diagnosis of PD. Cognitive impairment was a late feature in two out of three patients. Cortical involvement varied significantly: one had diffuse Lewy body (LB) pathology, tau inclusions, and amyloid pathology consistent with advanced Alzheimer's disease; one had diffuse cortical LB; and one had only brainstem predominant LB pathology. Cognitive impairment may be a long-term complication in G2019S mutation carriers. However, the extent of cortical involvement is variable. Larger longitudinal follow-up of LRRK2 G2019S mutation carriers is required to assess for risk factors for cortical involvement and dementia.
Introduction
LRRK2 G2019S mutations are among the most frequently identified genetic causes for Parkinson's disease (PD) (Healy et al. 2008) . The International LRRK2 Consortium study estimated G2019S mutation frequency at 1% of sporadic and 4% of familial PD patients (Healy et al. 2008 ). The highest frequency was found in North African Arabs (36% in familial, 39% in sporadic; Lesage et al. 2006) and Ashkenazi Jews (28% and 10%, respectively; Ozelius et al. 2006) . Clinically, G2019S mutation carriers who develop PD have a very similar disease to non-carriers, including the development of motor symptoms (e.g., rigidity and bradykinesia) and later cognitive difficulties (Healy et al. 2008; Belarbi et al. 2010 ).
Drug-induced dyskinesia happens frequently, but may happen later than in non-carriers (Healy et al. 2008) . The neuropathology of mutation carriers is heterogeneous. Twenty-five autopsy reports of LRRK2 G2019S mutation carriers have been published in the English literature. Twenty-two were obtained from patients with a clinical history of PD. Of these, 19 showed Lewy bodies (LBs) with variable neurofibrillary tangle burden (NFTs). Two had only tau inclusions, and one had no distinctive inclusions (Wider et al. 2010) . However, most studies, including ours, only screened autopsies of patients with a clinical history of PD. Only five of the autopsy studies reporting these G2019S mutation carriers screened patients with diagnoses other than PD (Gilks et al. 2005; Rajput et al. 2006; Ross et al. 2006; Dachsel et al. 2007; Gaig et al. 2008) . To further explore the pathological characteristics, we describe the autopsy findings of three LRRK2 G2019S mutation carriers.
Methods
We have genotyped 956 PD patients for the LRRK2 G2019S mutation in clinical studies at Columbia University (Marder et al. 2010) . Columbia University Institutional Review Board approved the protocols and consent procedures. Written informed consent was obtained from all participants in the study. Inclusion criteria for these studies required UK brain bank criteria for PD (Hughes et al. 1992; Daniel and Lees 1993) . We cross referenced the participants' list with 282 patients with parkinsonism who had an autopsy in our center since 1991, including 98 PD, 72 dementia with LB (DLB), 33 progressive supranuclear palsy (PSP), 31 multiple system atrophy (MSA), 18 corticobasal ganglionic degeneration (CBGD), 12 Alzheimer's disease (AD), five Alzheimer's disease Lewy body variant (ADLBV), seven frontotemporal lobar degeneration (FTLD), and six Creutzfeldt-Jakob disease (CJD) patients. We found three G2019S mutation carriers in our brain bank: two out of 98 PD and one out of five ADLBV patients. Pathological analyses of the samples were blind to the genetic findings. We retrospectively reviewed the clinical records of these three patients.
Results
Patient 1 presented at age 44 with right hand rest tremor, micrographia, and right foot dragging. PD was diagnosed. The patient had an excellent response to levodopa/carbidopa. Fifteen years after onset, dyskinesia developed on 750 mg/day of levodopa. Seventeen years after onset, adrenal medullary transplantation improved anxiety and imbalance for 2 years. Then, its effect dissipated. Twenty-six years after onset, falling resulted in physical dependence. Motor complications were improved by subthalamic nucleus deep brain stimulation, 32 years after onset. The patient died 34 years after onset at age 78. Cognitive decline was never documented. No other family member had been diagnosed with PD or other neurodegenerative disease.
Brain autopsy revealed severe neuronal loss in the dorsal nucleus of vagus (dnV), locus coeruleus (LC), and substantia nigra pars compacta (SNpc). LBs were present in the above locations. One LB was found in the substantia innominata (SI). Very rare NFTs were found in the Sommer sector of the hippocampal formation. Neuropathologic stage of PD (NSPD) according to Braak staging was 4/6 (Braak et al. 2003) (Fig. 1a, d , g, j, m, p).
Patient 2 presented at age 39 with right hand clenching, micrographia, and foot dragging. The patient was diagnosed with PD and had an excellent response to levodopa. Dyskinesia developed 5 years after onset on 700 mg/day of levodopa. The first fall occurred 9 years after onset. Seventeen years after onset, a left pallidotomy improved the motor complications; its effect dissipated 7 years later. Dementia was clinically diagnosed 24 years after onset of symptoms. The patient died 28 years after symptom onset. While there was no family history of PD, two siblings developed Crohn's disease.
Brain pathology showed severe neuronal loss in the LC and SNpc and moderate in the SI. LBs were found in the dnV, SNpc, hypothalamus, SI, amygdala, and rarely in the entorhinal cortex, cingulate gyrus (three per ×100 microscopic field), and prefrontal cortex (two throughout the slide). Rare NFTs were present in the Sommer sector, with few neuritic plaques in the parahippocampal gyrus. NSPD was 4/6 (Fig. 1b, e , h, k, n, q).
Patient 3 presented at age 53 with right hand rest tremor, micrographia, and depression. PD was diagnosed with very good response to levodopa/carbidopa. Ten years later, hyposmia was noted by the patient. Twelve years after onset, dyskinesia developed on 1,000 mg/day of levodopa. The first fall occurred 19 years into her illness. Twenty-one years after symptoms onset, dementia was diagnosed based on clinical impression. Marked worsening of imbalance, dementia, and depression preceded death at age 84. The duration of symptoms was 31 years. Family history of PD and AD was positive only in third-degree relatives. One sibling died of "colitis" as a young adult. Fig. 1 Pathological findings in three LRRK2 G2019S mutation carriers with PD. a-c [Luxol-hematoxylin-eosin (LHE) stain] shows Lewy bodies (LB)s in the substantia nigra pars compacta (SNpc) (magnification, ×400). d-f (Alpha-synuclein stain) depicts alpha-synuclein reactive LBs and Lewy neurites (LNs) in the SNpc (magnification, ×400). g-i (LHE stain) reveals LBs in the locus coeruleus (LC) (magnification, ×630). j, k (Substantia innominata) and l (motor cortex) shows LBs and LNs reactive to alpha-synuclein stain (magnification, ×200). m (LHE stain) shows a single NFT in the hippocampal formation cornus ammonis 1 (CA1). n, o (Bielschowsky) reveals NFTs and ghost tangles in CA1. p-r (AT8 stain) demonstrates tau-immunoreactive NFTs (magnification, ×200) b Autopsy showed severe neuronal loss in the LC, SNpc, and the hippocampal Sommer sector. Few LBs were noted in the above locations, dnV, hypothalamus, and the thalamus. Abundant LBs (up to 20 per ×100 microscopic filed) were found in the SI, amygdala, entorhinal, cingulate, temporal, prefrontal, and motor cortices. NFTs and neuritic plaques were few in the thalamus and striatum, but many in the amygdala, hippocampal formation, and in all cortical lobes. NSPD was 6/6. The pathological diagnosis was ADLBV (Lippa et al. 1994) (Fig. 1c, f, i, l, o, r) .
Discussion
The neuropathology associated with LRRK2 mutations is very heterogeneous and may include LB, tau inclusions, atrophy, and normal pathology. The type of the LRRK2 mutation may explain part of this heterogeneity, where most autopsies of the G2019S mutation' autopsies show LB pathology, while most of the R1441C and I2020T mutations do not. In fact, there is a pathological variability even within the same family as shown in the initial report of R1441C carriers (Zimprich et al. 2004) .
While most of the G2019S autopsies show LB pathology, the literature (including our report) may be biased towards LB pathology, as many autopsy studies genotyped patients with clinical or pathological diagnosis of PD (Giasson et al. 2006; Gaig et al. 2007; Silveira-Moriyama et al. 2008; Gomez and Ferrer 2010) . In particular, all nine autopsy studies, reporting on G2019S carriers, screened 891 patients with LB disorders (Gilks et al. 2005; Giasson et al. 2006; Rajput et al. 2006; Ross et al. 2006; Gaig et al. 2007 Gaig et al. , 2008 Silveira-Moriyama et al. 2008; Gomez and Ferrer 2010) , 363 with PSP (Rajput et al. 2006; Ross et al. 2006; Gaig et al. 2008) , 62 MSA (Rajput et al. 2006; Ross et al. 2006; Gaig et al. 2008) , seven CBGD (Rajput et al. 2006; Gaig et al. 2008) , 654 AD (Ross et al. 2006) , 59 FTLD (Rajput et al. 2006; Dachsel et al. 2007; Gaig et al. 2008) , 102 HD (Gilks et al. 2005) , 16 ET (Rajput et al. 2006) , and 444 controls (Rajput et al. 2006; Ross et al. 2006; Silveira-Moriyama et al. 2008) . However, publication bias may also exist, in that autopsies with uncommon findings are more likely to be reported.
None of the three patients reported here had a first-degree family history of PD. This may be partially explained by the incomplete penetrance of G2019S mutations (Ozelius et al. 2007) . Two patients had a first-degree family history of colitis. One patient had two siblings with Crohn's disease. LRRK2 has been associated with Crohn's disease in genomewide association studies (Umeno et al. 2011) ; however, the genotypes of these siblings with Crohn's in our cases are unknown.
All three cases reported here had brainstem LB pathology. However, these cases highlight the clinical and pathological heterogeneity of cortical involvement in LRRK2 G2019S mutation carriers. Clinically, cognitive performance in PD is diverse, but up to 83% of PD survivors after 20 years develop dementia (Hely et al. 2008 ). In our cases, dementia was present in two patients (disease duration was long in all three, ranging between 28 and 34 years). This sample is very small but not significantly dissimilar from idiopathic PD. On pathology, one case had little cortical involvement, one had LB involvement of the cortex, and one had ADLBV. In the latter, it is unknown whether there is a link between the G2019S genotype and the AD pathology. Cortical involvement has not been consistently reported in the literature. Of the 19 G2019S autopsies reported in the English literature with Lewy bodies, seven were reported to have extensive cortical involvement (NSPD stage 5-6), and 12 had brainstem-type PD (NSPD stages 3-4). Therefore, even in patients with the same genetic lesion, there is widely variable cortical involvement. Based on these cases, we hypothesize that other genetic and environmental risk factors predispose one to cortical involvement in G2019S mutation carriers. Larger series and longitudinal follow-up of LRRK2 G2019S mutation carriers are required to assess risk factors for cortical degeneration and dementia and to explore the pathological heterogeneity in autopsies.
